Interested in IVF Treatment?

Interested in Participation? Visit the Link Below

Pinnacle Fertility Oregon is currently prescreening participants for the GRACE Study, a multicenter investigational clinical trial evaluating a human menopausal gonadotropin (hMG) medication used during IVF treatment.

The GRACE Study is a randomized, placebo-controlled, double-blind clinical trial designed to evaluate the efficacy and safety of hMG in the development of multiple follicles, pregnancy rates, and cumulative live birth outcomes as part of an assisted reproductive technology (ART) cycle in women undergoing IVF.

Study Overview

Participants in the GRACE investigational study may undergo up to two IVF stimulation cycles with PGT-A (preimplantation genetic testing for aneuploidy) and, if eligible, up to three frozen embryo transfer (FET) cycles.

Inclusion Criteria

Participants must meet the following criteria:

• Premenopausal women aged 18–42 years

• BMI ≥18 and <38 kg/m²

• Regular menstrual cycles between 21–35 days

• AMH >1.2 ng/mL within 6 months prior to screening

• Absence of hydrosalpinx

Exclusion Criteria

Participants may not qualify if they have:

• Recurrent implantation failure

• Recurrent pregnancy loss

• Antral Follicle Count (AFC) <5

• Submucosal fibroids or intramural fibroids ≥5 cm

• Severe endometriosis (ASRM Stage III or IV)

Additional inclusion and exclusion criteria apply. For more information or to determine eligibility, please contact the study coordination team.

About the Sponsor

Granata Bio is a biopharmaceutical company focused on developing innovative therapies that improve outcomes and expand access in reproductive health.

For more information about the GRACE Investigational Study, visit:

• www.graceivfstudy.com

• ClinicalTrials.gov Identifier: NCT07216742